Skip to main content

Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

2,065 trials, most industry funding first

  1. PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

    Completed · Phase 1 · Advanced Solid Tumor

    NCT04887194 · Mirati Therapeutics, Inc. · 1 U.S. investigator

    $110,598research payments

  2. A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

    Recruiting · Phase 2 · Myelodysplastic Syndromes

    NCT04419649 · Takeda Pharmaceuticals U.S.A., Inc. · 5 U.S. investigators

    $110,493research payments

  3. Study of DSP-0390 in Patients With Recurrent High-Grade Glioma

    Active, not recruiting · Early phase 1 · High Grade Glioma

    NCT05023551 · Sumitomo Pharma America, Inc. · 4 U.S. investigators

    $110,296research payments

  4. A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy

    Recruiting · Duchene Muscular Dystrophy

    NCT07127978 · Itf Therapeutics LLC · 2 U.S. investigators

    $109,934research payments

  5. Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    Recruiting · Phase 1 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    NCT06859008 · Beone Medicines USA, Inc. · 1 U.S. investigator

    $109,820research payments

  6. A Study of DS5361b in Participants With Advanced Solid Tumors

    Recruiting · Phase 1 · Advanced Solid Tumor

    NCT07182591 · Daiichi Sankyo Inc. · 3 U.S. investigators

    $108,950research payments

  7. Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma

    Completed · Phase 3 · Open-Angle Glaucoma

    NCT05411198 · AbbVie Inc. · 11 U.S. investigators

    $108,599research payments

  8. A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)

    Active, not recruiting · Glycogen Storage Disease Type II

    NCT04848779 · Genzyme Corporation · 5 U.S. investigators

    $108,313research payments

  9. A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

    Completed · Phase 2 · Obesity

    NCT04881760 · Eli Lilly and Company · 2 U.S. investigators

    $108,117research payments

  10. Real World Evidence Clinical Utility Study of KidneyIntelX

    Recruiting · Chronic Kidney Diseases

    NCT04802395 · Renalytix Ai, Inc. · 1 U.S. investigator

    $108,000research payments

  11. A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

    Terminated · Phase 3 · Chronic Kidney Disease (CKD)

    NCT04064827 · AbbVie Inc. · 7 U.S. investigators

    $107,810research payments

  12. A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity

    Completed · Phase 1 · Obesity

    NCT05696847 · Eli Lilly and Company · 3 U.S. investigators

    $106,771research payments

  13. A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2

    Terminated · Phase 3 · Tay-Sachs Disease

    NCT04221451 · Sanofi US Services Inc. · 4 U.S. investigators

    $106,627research payments

  14. A Study of LAD191 in Adults With Hidradenitis Suppurativa

    Recruiting · Phase 2 · Hidradenitis Suppurativa

    NCT07151937 · Almirall LLC · 4 U.S. investigators

    $106,423research payments

  15. rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance

    Recruiting · Early phase 1 · Prostate Adenocarcinoma

    NCT05852041 · Blue Earth Diagnostics · 1 U.S. investigator

    $106,382research payments

  16. Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

    Recruiting · Phase 3 · Hemophilia B

    NCT06003387 · Csl Behring · 2 U.S. investigators

    $106,307research payments

  17. A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

    Completed · Phase 1 · Melanoma

    NCT02009449 · Eli Lilly and Company · 1 U.S. investigator

    $105,784research payments

  18. Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

    Recruiting · Phase 1, Phase 2 · Low-grade Upper Tract Urothelial Carcinoma

    NCT06668493 · Ferring Pharmaceuticals As · 3 U.S. investigators

    $105,611research payments

  19. Spinal Cord Stimulation in the Treatment of Chronic, Intractable Pain Using the Nalu™ Neurostimulation System

    Completed · Not applicable · Pain, Chronic

    NCT04503109 · Nalu Medical, Inc. · 11 U.S. investigators

    $105,456research payments

  20. Cognition and Imaging With Tigertriever

    Recruiting · Stroke

    NCT05531461 · Rapid Medical Ltd · 2 U.S. investigators

    $105,349research payments

  21. A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

    Completed · Phase 3 · Atopic Dermatitis

    NCT05601882 · AbbVie Inc. · 15 U.S. investigators

    $105,028research payments

  22. Copper Histidinate Treatment for Menkes Disease

    Approved for marketing · Menkes Disease

    NCT04074512 · Sentynl Therapeutics, Inc. · 5 U.S. investigators

    $104,089research payments

  23. CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

    Completed · Phase 3 · Hereditary Angioedema (HAE)

    NCT05819775 · Csl Behring · 3 U.S. investigators

    $104,088research payments

  24. A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)

    Active, not recruiting · Retinitis Pigmentosa

    NCT06517940 · Sumitomo Pharma America, Inc. · 1 U.S. investigator

    $104,087research payments

  25. A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

    Recruiting · Phase 1 · Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)

    NCT06801223 · La Jolla Pharmaceutical Company · 3 U.S. investigators

    $103,398research payments

  26. G7 Dual Mobility With Vivacit-E or Longevity PMCF

    Enrolling by invitation · Not applicable · Hip Osteoarthritis

    NCT05548972 · Zimmer Biomet Holdings, Inc. · 5 U.S. investigators

    $103,381research payments

  27. SpO2 Validation Study-Philips Optimus

    Terminated · Pulse Oximetry, Oxygen Measurements, SpO2

    NCT07215429 · Philips North America LLC · 2 U.S. investigators

    $103,277research payments

  28. Vis-Rx Prime Micro-Imaging Catheter Study

    Completed · Coronary Artery Disease

    NCT06685783 · Gentuity, LLC · 3 U.S. investigators

    $103,010research payments

  29. A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

    Terminated · Phase 1 · Multiple Myeloma, Refractory

    NCT05121103 · Epizyme, Inc. · 5 U.S. investigators

    $102,732research payments

  30. Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis

    Completed · Phase 2 · Relapsing Multiple Sclerosis

    NCT03996291 · Genzyme Corporation · 6 U.S. investigators

    $102,579research payments

  31. A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

    Completed · Phase 1 · Small Cell Lung Cancer

    NCT03639194 · AbbVie Inc. · 5 U.S. investigators

    $102,504research payments

  32. Observational Study to Assess Transradial Access for Treatment in the Lower Extremities.

    Completed · Peripheral Arterial Disease

    NCT04371861 · Terumo Medical Corporation · 1 U.S. investigator

    $102,000research payments

  33. A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

    Recruiting · Phase 4 · Chronic Obstructive Pulmonary Disease

    NCT07053423 · Genzyme Corporation · 4 U.S. investigators

    $100,955research payments

  34. Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)

    Active, not recruiting · Not applicable · Ascites

    NCT03973866 · Sequana Medical US Inc. · 3 U.S. investigators

    $100,536research payments

  35. Acute Renal Failure Trial Network (ATN) Study

    Completed · Phase 3 · Acute Renal Failure

    NCT00076219 · Vantive US Healthcare LLC · 1 U.S. investigator

    $100,000research payments

  36. Rezafungin Prophylaxis in Liver Transplant

    Enrolling by invitation · Phase 3 · Liver Transplant Infection

    NCT06774144 · Melinta Therapeutics, LLC · 2 U.S. investigators

    $100,000research payments

  37. Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

    Active, not recruiting · Phase 1 · Advanced or Metastatic NSCLC

    NCT04526691 · Daiichi Sankyo Inc. · 5 U.S. investigators

    $99,649research payments

  38. A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

    Completed · Phase 3 · Psoriatic Arthritis

    NCT03104400 · AbbVie Inc. · 8 U.S. investigators

    $99,492research payments

  39. NIBP Validation Study

    Recruiting · Critical Illness

    NCT05673408 · Philips North America LLC · 3 U.S. investigators

    $99,082research payments

  40. Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

    Recruiting · Phase 2 · Hidradenitis Suppurativa

    NCT07170917 · Sanofi US Services Inc. · 5 U.S. investigators

    $98,930research payments

  41. Intracardiac Echocardiography Guided Watchman Device Implant

    Recruiting · Not applicable · Atrial Fibrillation

    NCT06007872 · Philips North America LLC · 1 U.S. investigator

    $98,855research payments

  42. Clinical Exploration of NEUROMARK System in Participants With Chronic Migraine

    Completed · Not applicable · Chronic Migraine Headache

    NCT06862674 · Neurent Medical Limited · 0 U.S. investigators

    $98,309research payments

  43. Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension

    Active, not recruiting · Phase 2 · Gaucher Disease Type 1

    NCT02843035 · Genzyme Corporation · 1 U.S. investigator

    $98,258research payments

  44. Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults

    Completed · Phase 1 · Smallpox

    NCT05935917 · Emergent Biosolutions Inc. · 0 U.S. investigators

    $97,904research payments

  45. The ACES Study for Aseptic Pleural Effusion

    Active, not recruiting · Not applicable · Pleural Effusion

    NCT06210685 · Pleural Dynamics Inc. · 4 U.S. investigators

    $97,695research payments

  46. Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

    Completed · Phase 3 · Hematological Malignancies

    NCT02730299 · Gamida Cell Inc. · 5 U.S. investigators

    $97,189research payments

  47. CERAMENT G Device Registry

    Recruiting · Chronic Osteomyelitis

    NCT06010433 · Bone Support Ab · 3 U.S. investigators

    $96,902research payments

  48. Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

    Active, not recruiting · Phase 3 · Myelofibrosis (MF)

    NCT04468984 · AbbVie Inc. · 16 U.S. investigators

    $96,283research payments

  49. Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

    Recruiting · Phase 2 · Chronic Lymphocytic Leukemia

    NCT06839053 · Beone Medicines USA, Inc. · 1 U.S. investigator

    $96,053research payments

  50. Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX

    Completed · Phase 3 · Hemophilia

    NCT03754790 · Sanofi US Services Inc. · 4 U.S. investigators

    $95,652research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.

About this page

Industry-funded clinical trials test new drugs and devices in patients. This list shows trials for which drug and device companies reported research payments to CMS, linked to their ClinicalTrials.gov records. For each trial, you can see the sponsor, phase and status, the U.S. physicians named as principal investigators, and how much the company paid for the research.

How to search industry-funded clinical trials

First, search by drug, condition or company. Then open a trial to see its investigators and study sites. You can also start from a doctor’s page, which lists the trials that doctor helps lead. In addition, drug and specialty pages link to the trials in their field.

What the payments mean

Research payments usually go to hospitals and universities to run the study. In other words, the money pays for the research, not the investigator personally. Companies report these payments under the federal Sunshine Act, and CMS publishes them in Open Payments (opens in a new tab). However, a payment record alone does not show how a study was run or what it found.

Joining a clinical trial

If you want to join a trial, start with the official record on ClinicalTrials.gov (opens in a new tab). It lists who can take part, where and how to contact the study team. Also talk to your doctor first, because a trial may not be right for you.

Related: Medicare drugs, drug company payments to doctors, specialties.

Questions about industry-funded clinical trials

Are industry-funded clinical trials safe? Every trial in the U.S. needs approval from an ethics board, and drug trials also follow FDA rules. However, every trial carries some risk. So read the consent form carefully and ask questions.

Who is a principal investigator? The principal investigator is the doctor who leads the study at a site. Their page here shows their other trials and the payments companies reported for that research.

Why are some trials missing? We list trials with industry research payments in Open Payments. As a result, trials funded only by the government or universities do not appear.